Steven Cohen Sarepta Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 36,855 shares of SRPT stock, worth $4.47 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

36,855

Previous 48,913 24.65%

Holding current value

$4.47 Million

Previous $7.73 Million 40.44%

% of portfolio

0.01%

Previous 0.02%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$124.33 - $156.75 $1.5 Million - $1.89 Million	-12,058 Reduced 24.65%	36,855 $4.6 Million
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $5.54 Million - $8.01 Million	48,913 New	48,913 $7.73 Million
Q3 2023 Nov 14, 2023	SELL	$102.5 - $123.59 $2.26 Million - $2.72 Million	-22,026 Reduced 6.69%	307,343 $37.3 Million
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $29.9 Million - $44.2 Million	280,913 Added 579.73%	329,369 $37.7 Million
Q1 2023 May 15, 2023	SELL	$117.53 - $155.99 $77 Million - $102 Million	-655,299 Reduced 93.11%	48,456 $6.68 Million
Q4 2022 Feb 14, 2023	SELL	$100.86 - $132.13 $14.9 Million - $19.6 Million	-148,145 Reduced 17.39%	703,755 $91.2 Million
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $32.3 Million - $50.8 Million	426,393 Added 100.21%	851,900 $94.2 Million
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $64.1 Million - $90.4 Million	-1,021,704 Reduced 70.6%	425,507 $31.9 Million
Q1 2022 May 16, 2022	BUY	$63.15 - $90.42 $18.7 Million - $26.8 Million	296,002 Added 25.71%	1,447,211 $113 Million
Q4 2021 Feb 14, 2022	SELL	$77.28 - $99.42 $53.7 Million - $69.1 Million	-694,791 Reduced 37.64%	1,151,209 $104 Million
Q3 2021 Nov 15, 2021	BUY	$65.97 - $92.48 $94.2 Million - $132 Million	1,427,400 Added 340.99%	1,846,000 $171 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $19.4 Million - $24.3 Million	279,614 Added 201.18%	418,600 $32.5 Million
Q1 2021 May 17, 2021	BUY	$72.25 - $168.95 $10 Million - $23.5 Million	138,986 New	138,986 $10.4 Million
Q1 2020 May 15, 2020	SELL	$82.38 - $131.64 $28.4 Million - $45.4 Million	-344,710 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $26.9 Million - $47.7 Million	-351,975 Reduced 50.52%	344,710 $44.5 Million
Q3 2019 Nov 15, 2019	BUY	$72.81 - $156.91 $50.7 Million - $109 Million	696,685 New	696,685 $52.5 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $29.3 Million - $39.6 Million	-260,790 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $19.5 Million - $27.7 Million	182,897 Added 234.81%	260,790 $31.1 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $1.18 Million - $1.8 Million	12,123 Added 18.43%	77,893 $8.5 Million
Q3 2018 Nov 14, 2018	SELL	$115.31 - $161.51 $23.1 Million - $32.3 Million	-199,991 Reduced 75.25%	65,770 $10.6 Million
Q2 2018 Aug 14, 2018	SELL	$71.74 - $153.69 $22.5 Million - $48.3 Million	-313,996 Reduced 54.16%	265,761 $35.1 Million
Q4 2017 Feb 14, 2018	SELL	$47.64 - $56.75 $50.8 Million - $60.5 Million	-1,065,518 Reduced 64.76%	579,757 $32.3 Million
Q3 2017 Nov 14, 2017	BUY	$35.73 - $47.15 $58.8 Million - $77.6 Million	1,645,275	1,645,275 $74.6 Million

Others Institutions Holding SRPT

# of Institutions

529

Shares Held

84.2M

Call Options Held

2.06M

Put Options Held

1.52M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.6B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account